ABSI
Absci Corp
NASDAQ · Healthcare · Biotechnology · US
$8.25
−7.09%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$8.81
From 52W high−29.00%
Volume3.46M
Market cap$1.42B
P/E (TTM)—
P/S (TTM)907.0x
Div yield—
Key dataOct 16, 2026
Open
$8.81
From 52W high
−29.00%
Volume
3.46M
Market cap
$1.42B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.1x
P/E (TTM)
—
RSI (14)
41.3
MomentumView details →
1D Return
−7.09%
YTD Return
+137.68%
SummaryUpdated Jun 1, 2026
Absci Corporation (NASDAQ:ABSI) is a biotechnology company founded in 2011 and headquartered in Vancouver, Washington. The company went public in July 2021 and operates as a drug and target discovery company that leverages artificial intelligence to create biologic drug candidates. Absci has developed an integrated drug creation platform that unifies traditional drug discovery and cell line development processes, enabling the design of antibodies for previously challenging or "undruggable" targets.
Similar companies
Latest newsMore news →
Absci announced that it will report business updates and third-quarter 2026 financial and operating results before market open on November 12, 2026.3d agoAbsci announced preliminary details for its Phase 2 STORYLINE trial of AI-designed antibody ABS-201 for endometriosis, with initiation anticipated in mid-2027.22d agoAbsci released positive interim data from its Phase I hair loss study for ABS-201, showing the drug is well tolerated and supports infrequent dosing.113d ago